267 related articles for article (PubMed ID: 21957197)
1. Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure.
Cao G; Beyer TP; Zhang Y; Schmidt RJ; Chen YQ; Cockerham SL; Zimmerman KM; Karathanasis SK; Cannady EA; Fields T; Mantlo NB
J Lipid Res; 2011 Dec; 52(12):2169-2176. PubMed ID: 21957197
[TBL] [Abstract][Full Text] [Related]
2. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.
Mohammadpour AH; Akhlaghi F
Clin Pharmacokinet; 2013 Aug; 52(8):615-26. PubMed ID: 23658137
[TBL] [Abstract][Full Text] [Related]
3. Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubility.
Kalgutkar AS; Frederick KS; Hatch HL; Ambler CM; Perry DA; Garigipati RS; Chang GC; Lefker BA; Clark RW; Morehouse LA; Francone O; Hu X
Xenobiotica; 2014 Jul; 44(7):591-605. PubMed ID: 24380613
[TBL] [Abstract][Full Text] [Related]
4. On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.
Johns DG; Duffy J; Fisher T; Hubbard BK; Forrest MJ
Drugs; 2012 Mar; 72(4):491-507. PubMed ID: 22356288
[TBL] [Abstract][Full Text] [Related]
5. Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase.
Simic B; Mocharla P; Crucet M; Osto E; Kratzer A; Stivala S; Kühnast S; Speer T; Doycheva P; Princen HM; van der Hoorn JW; Jukema JW; Giral H; Tailleux A; Landmesser U; Staels B; Lüscher TF
Atherosclerosis; 2017 Feb; 257():186-194. PubMed ID: 28152406
[TBL] [Abstract][Full Text] [Related]
6. Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adults.
Suico JG; Wang MD; Friedrich S; Cannady EA; Konkoy CS; Ruotolo G; Krueger KA
J Pharm Pharmacol; 2014 Nov; 66(11):1576-85. PubMed ID: 24961753
[TBL] [Abstract][Full Text] [Related]
7. No cardiovascular benefit with evacetrapib - is this the end of the road for the 'cetrapibs'?
Doggrell SA
Expert Opin Pharmacother; 2017 Oct; 18(14):1439-1442. PubMed ID: 28799819
[TBL] [Abstract][Full Text] [Related]
8. Evacetrapib: Another CETP Inhibitor for Dyslipidemia With No Clinical Benefit.
Eyvazian VA; Frishman WH
Cardiol Rev; 2017; 25(2):43-52. PubMed ID: 28099220
[TBL] [Abstract][Full Text] [Related]
9. Evacetrapib.
Nicholls SJ
Curr Cardiol Rep; 2012 Jun; 14(3):245-50. PubMed ID: 22362199
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological Inhibition of CETP (Cholesteryl Ester Transfer Protein) Increases HDL (High-Density Lipoprotein) That Contains ApoC3 and Other HDL Subspecies Associated With Higher Risk of Coronary Heart Disease.
Furtado JD; Ruotolo G; Nicholls SJ; Dullea R; Carvajal-Gonzalez S; Sacks FM
Arterioscler Thromb Vasc Biol; 2022 Feb; 42(2):227-237. PubMed ID: 34937388
[TBL] [Abstract][Full Text] [Related]
11. Rationale for cholesteryl ester transfer protein inhibition.
Hewing B; Fisher EA
Curr Opin Lipidol; 2012 Aug; 23(4):372-6. PubMed ID: 22517614
[TBL] [Abstract][Full Text] [Related]
12. Cholesteryl ester transfer protein (CETP) deficiency and CETP inhibitors.
Mabuchi H; Nohara A; Inazu A
Mol Cells; 2014 Nov; 37(11):777-84. PubMed ID: 25410905
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety, tolerability, and pharmacokinetic profile of evacetrapib administered as monotherapy or in combination with atorvastatin in Japanese patients with dyslipidemia.
Teramoto T; Takeuchi M; Morisaki Y; Ruotolo G; Krueger KA
Am J Cardiol; 2014 Jun; 113(12):2021-9. PubMed ID: 24786356
[TBL] [Abstract][Full Text] [Related]
14. Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk?
Schaefer EJ
Curr Opin Lipidol; 2013 Jun; 24(3):259-64. PubMed ID: 23652567
[TBL] [Abstract][Full Text] [Related]
15. Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists.
Yamashita S; Ruscica M; Macchi C; Corsini A; Matsuzawa Y; Sirtori CR
Atherosclerosis; 2018 Nov; 278():286-298. PubMed ID: 30347344
[TBL] [Abstract][Full Text] [Related]
16. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
Nicholls SJ; Brewer HB; Kastelein JJ; Krueger KA; Wang MD; Shao M; Hu B; McErlean E; Nissen SE
JAMA; 2011 Nov; 306(19):2099-109. PubMed ID: 22089718
[TBL] [Abstract][Full Text] [Related]
17. Cholesteryl ester transfer protein inhibitors: challenges and perspectives.
Filippatos TD; Klouras E; Barkas F; Elisaf M
Expert Rev Cardiovasc Ther; 2016 Aug; 14(8):953-62. PubMed ID: 27171534
[TBL] [Abstract][Full Text] [Related]
18. Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?
Nurmohamed NS; Ditmarsch M; Kastelein JJP
Cardiovasc Res; 2022 Nov; 118(14):2919-2931. PubMed ID: 34849601
[TBL] [Abstract][Full Text] [Related]
19. Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib.
Nicholls SJ; Ruotolo G; Brewer HB; Kane JP; Wang MD; Krueger KA; Adelman SJ; Nissen SE; Rader DJ
J Am Coll Cardiol; 2015 Nov; 66(20):2201-2210. PubMed ID: 26564598
[TBL] [Abstract][Full Text] [Related]
20. Safety of CETP inhibition.
Duivenvoorden R; Fayad ZA
Curr Opin Lipidol; 2012 Dec; 23(6):518-24. PubMed ID: 23010697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]